Fundz

VitriVax, Inc. announces $87 million Series C financing co-led by F-Prime, NEA, and others to advance its Lyme disease vaccine candidate into the clinic.

PRIVATENov 18, 2026

Amount Raised

$87 Million

Round Type

Series C

BoulderBiotechnologyTherapeutics

Investors

Eli Lilly And CompanySanofi VenturesRA Capital ManagementNew Enterprise AssociatesF Prime

Description

VitriVax, Inc. has closed an oversubscribed $87 million Series C financing round. The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures, with participation from Eli Lilly and Company and other existing investors. The funds will be used to advance VitriVax’s lead program, a Lyme disease vaccine with a novel mechanism of action

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Vitri Vax that raised within 45 days of this round, from Fundz verified event records.

  • Commit Biologics raised $60M (Seed) on November 17, 2026.
  • Onward Therapeutics SA raised $28M (Series B) on November 17, 2026.
  • 201 Therapeutics raised $178K (Seed) on November 16, 2026.
  • Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
  • Yicura BioMed raised an undisclosed amount (Series B) on November 13, 2026.

Who to call at Vitri Vax, and when

A new round usually means Vitri Vax is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vitri Vax raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vitri Vax, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vitri Vax. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vitri Vax

Location

Boulder, Colorado, United States

About

VitriVax is a Boulder, Colorado- and Boston, Massachusetts-based biotechnology company working to eliminate barriers to global vaccination. VitriVax partners with vaccine developers to formulate their vaccines to be thermostable and delivered in a single shot. Products formulated by the VitriVax ALTATM platform can be shipped globally without refrigeration or freezing, last for years on the shelf, and only require one patient interaction to deliver multiple doses. For more information, visit www.vitrivaxbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vitri Vax raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Vitri Vax's next move

See what Strategic adds

Vitri Vax raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.